Murine Brca1 is widely expressed during development in different tissues. Why alterations of BRCA1 lead specifically to breast and ovarian cancer is currently not clarified. Here we show that Brca1 protein expression is upregulated during mammary epithelial differentiation of HC11 cells, during differentiation of C2C12 myoblasts into myotubes and during neuronal differentiation of N1E-115 cells. Ectopic overexpression of BRCA1 and downregulation of endogenous Brca1 expression specifically affect the regulation of mammary epithelial cell differentiation. Accelerated mammary epithelial cell differentiation upon high ectopic BRCA1 expression is not a consequence of the anti-proliferative capacity of this tumor suppressor and independent of functional p53. Overexpression of the BRCA1 variant lacking the large central exon 11 has no effects on mammary epithelial cell differentiation. These data provide new insights into the cellular role of Brca1.
Introduction
Mutations of the breast cancer susceptibility gene BRCA1 predispose to breast and ovarian cancer. The BRCA1 gene is composed of 23 exons. Over half of the 1863-amino-acid protein is encoded by an unusually large exon 11, which is 3.4 kb in length. Several different proteins have been shown to interact with BRCA1, including e.g. RAD51, RAD50, SWI/SNF, BARD1, RNA Pol II holoenzyme, E2F, c-Myc, p53 and retinoblastoma protein (pRb) . A large number of diverse functions, such as its ability to regulate the maintenance of genome integrity, cell cycle control, apoptosis and DNA repair, have been attributed to BRCA1 (for recent reviews see Zheng et al., 2000; Wang et al., 2000; Welcsh et al., 2001; Kerr and Ashworth, 2001) . The facts that BRCA1 is ubiquitously expressed and harbours such universal 'gatekeeper' functions, which do not appear to be cell-type specific, raise the question why mutations in BRCA1 lead specifically to breast and ovarian cancer. One possibility to account for this paradox is that BRCA1, apart from their universal activities, exerts distinct functions in breast and ovarian tissues (Zheng et al., 2000) .
In addition to the full-length BRCA1 protein mammalian cells contain alternatively spliced variants, BRCA1-D11 and BRCA1-D11b, which lack all and most of exon 11, respectively (Thakur et al., 1997; Wilson et al., 1997; Huber et al., 2001) . Brca1 homozygous deletions in the mouse are lethal at early embryonic development (E)5.5 -13.5. These embryos exhibited phenotypic variations, displaying severe developmental delays such as defects in neuronal development, including anencephaly and spina bifida. Murine embryos with targeted mutations selectively abolishing the expression of full-length Brca1 but intact expression of Brca1-D11 survive significantly longer (E12 -18.5) than embryos with mutations abolishing the expression of both Brca1 and Brca1-D11. These data provide evidence that Brca1-D11 can partially compensate for the functions of full-length Brca1 in mouse cells (Gowen et al., 1996; Hakem et al., 1996; Liu et al., 1996; Ludwig et al., 1997; Shen et al., 1998; Xu et al., 1999b) .
Examination of the developmental expression of murine Brca1 implied that it is involved in the processes of proliferation and differentiation in multiple tissues. The expression of murine Brca1 (and human BRCA1) has been shown to be regulated during the process of mammary gland development in vivo and in vitro (Marquis et al., 1995; Lane et al., 1995; Rajan et al., 1996; Daniel, 1999; Magdinier et al., 1999; Mixon et al., 2000) . These data, together with the dramatically elevated risks of breast cancer observed in woman carrying germ-line mutations in BRCA1, suggest that this gene plays an important role in the regulation of mammary epithelial cell development. To create a mouse model for Brca1 associated tumorigenesis a Cre -loxP approach was used to mutate Brca1 specifically in mouse mammary epithelial cells. Conditional downregulation of Brca1 expression caused increased apoptosis and aberrant mammary development. A model was proposed that disruption of Brca1 in the mammary gland could inhibit its growth (Xu et al., 1999a) .
Further investigation of BRCA1's contribution to mammary epithelial cell differentiation should provide new insights for the understanding of the normal cellular role of Brca1 and might contribute to the question how this gene, when mutant, specifically leads to breast cancer. How is Brca1 protein regulated during mammary epithelial cell differentiation in vitro? Is this regulation specific for this type of differentiation? Does modulation of Brca1 expression affect mammary epithelial cell differentiation? Can Brca1 trigger such effects specifically in mammary epithelial cells? Are these effects dependent on the endogenous status of pRb or p53, and are they coupled to Brca1's capacity to regulate cell proliferation? Can the naturally occuring BRCA1-D11 variant affect mammary epithelial cell differentiation? This study addressed these questions using murine cell systems for in vitro mammary epithelial, neuronal and muscle differentiation.
Results

Brca1 protein expression during in vitro differentiation
HC11 mammary epithelial cells were differentiated in the presence of lactogenic hormones. Differentiation was monitored detecting the induction of b-casein expression and the formation of domes (Figure 1 ). In the course of such experiments cell differentiation occured continuously and could be followed over 2 weeks. Western blot analysis demonstrated an upregulation of the steady state levels of Brca1 protein upon differentiation. For all Western blots protein loading was checked by Ponceau-S staining. In addition either blots were reprobed with a-tubulin or non-specific bands (NB) are presented, which we know from several experiments not to be regulated during differentiation. Here it is important to note that in Figure 1a in the first lane (undiff) more protein was loaded to enable visualization of the low amount of Brca1 protein, which is represented by a stronger non-specific band. Flowcytometric analysis of DNA distribution demonstrated that proliferation decreased and remained low in differentiating cells (Figure 1 ). C2C12 myoblasts fuse into myotubes upon induction of differentiation (Figures 2 and 5c ). Reproducibly, all cells were shifted from the undifferentiated to the differentiated status at about day 4 -5 of differentiation. Myogenin protein expression is upregulated during this process ( Figure  2 ). Immunoblot analysis and flowcytometric investigations demonstrated an upregulation of Brca1 protein accompanied by a downregulation of proliferation during muscle differentiation of C2C12 cells ( Figure   Figure 1 Brca1 expression during mammary epithelial cell differentiation. (a) HC11 cells were differentiated by adding differentiation medium 3 days after reaching confluency. At the indicated time points Brca1 protein expression was detected by Western blot analysis (antibody H-100, Santa Cruz). NB, non-specific bands, which are presented to visualize the amounts of protein loaded. In case of undifferentiated cells (undiff) more protein was loaded to enable detection of the relatively low amounts of Brca1 protein compared to differentiated cells. In addition, cells were harvested and cytofluorometrically analysed for distribution in different cell cycle phases. Figure 4 ). HC11 mammary epithelial cell differentiation is represented by an upregulation of the formation of domes. Overexpression of BRCA1 in undifferentiated HC11 cells did not induce this differentiation process (data not shown). Quantification of dome formation revealed that ectopic expression of BRCA1 promoted the process of mammary epithelial cell differentiation upon treatment with lactogenic hormones. To evaluate the significance of the observed differences statistical analysis was performed. The P value for the difference in number of domes at day 7 was 0.002, for the difference at day 9 of differentiation P=0.001 (Figure 4c ). In addition, we also investigated whether the effects of ectopic BRCA1 on HC11 differentiation are a consequence of deregulation of b-casein expression. We studied whether transfection of BRCA1 could induce b-casein mRNA expression in undifferentiated HC11 cells. Semiquantitative RT -PCR revealed that this was not the case (data not shown). Investigation of the question whether b-casein expression was elevated in BRCA1-transfected cells during lactogenic hormoneinduced differentiation compared to differentiation of control cells was hampered by two facts: (1) although b-casein expression was shut on as an early consequence of differentiation and remained expressed throughout the entire differentiation experiment, the quantitative levels varied between the different time points ( Figure 1b) ; (2) only small differences could be expected from the quantification of the effects of ectopic BRCA1 via estimation of dome formation as Brca1 in mammary epithelial cell differentiation M Kubista et al described above. What we can tell from RT -PCR experiments (performed with RNA extracts from cells at day 4 and 9 of differentiation) is that transfection of BRCA1 did not deregulate b-casein mRNA expression during differentiation of HC11 cells (data not shown).
We next overexpressed BRCA1 in C2C12 myoblasts. Quantification of cell fusion into myotubes was performed as described in Materials and methods. We quantified myotube fusion at different time points within days 2 -4 after induction of differentiation, since under the here described conditions differentiation was normally completed at day 4 -5. Comparing BRCA1 overexpressing cells with control transfectants did not reveal any significant differences ( Figure 5 and data not shown). In the course of these experiments we did not detect any signs of elevated apoptosis in HC11 and C2C12 cells (data not shown). Unfortunately, we could not succeed in generating BRCA1 overexpressing N1E-115 cells. These findings demonstrate that ectopic high levels of BRCA1 protein promote mammary epithelial cell differentiation but have no effects in muscle cells.
Downregulation of Brca1 expression attenuates mammary epithelial cell differentiation
To further explore the impact of Brca1 on these in vitro differentiations we performed antisense oligonucleotide experiments. HC11 cells were simultaneously treated with Brca1-specific antisense oligonucleotides and induced to differentiate by lactogenic hormones. Antisense treatment induced significant downregulation of Brca1 protein expression compared to extracts of cells treated with a control oligonucleotide ( Figure  6a ). Again, the status of differentiation was monitored via counting of dome formation at different time points after addition of lactogenic hormones. These experiments revealed that downregulation of Brca1 protein expression negatively affects the differentiation process. These negative effects could even already be visualized 3 days after induction of differentiation ( Figure 6b and data not shown). This approach was (a) G418-selectable mammalian expression vectors, empty as negative control or harboring full-length human BRCA1 cDNA, were transfected into HC11 cells. Transfected cells, kept under selection, were differentiated by adding differentiation medium 3 days after reaching confluency. Expression of ectopic BRCA1 mRNA was proven by RT -PCR 24 h after transfection and at day 9 of differentiation with set 1 of specific oligonucleotides (lanes 1 -3 and 7 -9) and set 2 of specific oligonucleotides (lanes 4 -6 and 10 -12). Lanes 1, 4, 7, 10=cells transfected with the empty vector control; lanes 2, 5, 8, 11=cells transfected with the BRCA1 plasmid; lanes 3, 6, 9, 12=water control. (b) Overexpression of BRCA1 protein was proven by Western blot analysis (antibody C-20, Santa Cruz). Amounts of loaded protein were investigated by reprobing with anti-a-tubulin antibody. (c) Transfected cells, kept under selection, were differentiated with lactogenic hormones. Domes, specifically formed during differentiation of HC11 cells, were counted at days 7 and 9 of treatment with differentiation medium. The control experiments have been set as 100%. Data of nine independent experiments are presented+standard deviations Brca1 in mammary epithelial cell differentiation M Kubista et al also chosen to test the effects of downregulation of Brca1 in C2C12 and N1E-115 cells. Quantification of differentiation at different time points revealed that Brca1-specific antisense treatment did neither affect muscle nor neuronal differentiation compared to experiments using the control oligonucleotide (data not shown). In the course of these antisense experiments we could not detect any sign of elevated apoptosis (data not shown). These data allow to conclude that downregulation of Brca1 expression specifically attenuates mammary epithelial cell differentiation.
BRCA1 influences mammary epithelial cell differentiation independently of anti-proliferative effects
Differentiation of HC11, C2C12 and N1E-115 cells is accompanied by downregulation of proliferation (Figures 1 -3 ). High levels of Brca1 have been shown to inhibit or attenuate proliferation of specific cells and cell lines (Holt et al., 1996; Aprelikova et al., 1999) . Accordingly, one could assume that overexpression of BRCA1 specifically arrests HC11 cells, which thereby become more susceptible to the differentiation process.
To test this hypothesis we transfected HeLa, HC11 and C2C12 cells with the BRCA1-expression plasmid (and with the empty control vector) and selected for transfected cells. So obtained cell pools were harvested, equal cell numbers were reseeded and cell numbers were estimated by cell counting at different time points. These experiments demonstrated that high levels of BRCA1 inhibit cell proliferation of HeLa cells, but not of HC11. Under the conditions of the here presented experiments BRCA1 even positively influenced the proliferation rate of HC11 cells (Figure 7a) . One explanation for different cellular reactions on high levels of BRCA1 has recently been provided. It was reported that only pRb-positive cells can be arrested by BRCA1, whereas the proliferation of pRb-negative cells remains unaffected (Aprelikova et al., 1999) . Accordingly, we wanted to obtain some information on whether different status of pRb could be responsible for the observed cell type specific effects of BRCA1 on in vitro differentiation. The cell cycledependent phosphorylation of pRb can be detected by immunoblot analysis of a shift from hyperphosphorylated slower migrating forms to hypophosphorylated faster migrating forms when logarithmically cycling cells are arrested by growing to confluency. Western blot analysis of cycling and confluent HeLa, HC11 and C2C12 cells revealed that all three cell lines express pRb protein. Furthermore, the expected shift in pRb forms could be detected in HC11 and C2C12 cells, but not in HeLa cells. The latter is consistent with the observation that confluent HeLa cells were not cell cycle arrested (Figure 7b ).
These findings suggest that BRCA1's cell type specific contribution to the regulation of differentiation is not coupled to its capacity to negatively regulate cell proliferation. In addition, the cell type specific control of proliferation and differentiation is probably not exclusively due to the specific presence or absence of endogenous pRb protein.
BRCA1-D11 and mammary epithelial cell differentiation
We also wanted to test whether the naturally occuring variant BRCA1-D11 can fulfil the function of fulllength BRCA1 in our assays. HC11 cells were transfected with a G418-selectable mammalian expression vector, empty as negative control and harboring the human BRCA1-D11 cDNA. Transfected cells were selected and differentiated as described above. Quantification of dome formation demonstrated that the (Figure 8 ).
Discussion
We demonstrate that high levels of BRCA1 promote mammary epithelial cell differentiation in vitro, but have no effect on muscle differentiation. Our data also show that ectopic expression of BRCA1 alone is not sufficient to induce HC11 cell differentiation in the absence of lactogenic hormones. Antisense experiments further revealed that downregulation of endogenous Brca1 expression attenuates differentiation of HC11 cells, but not muscle or neuronal differentiation. It has earlier been shown that downregulation of Brca1 expression causes aberrant mammary development (Xu et al., 1999a) . Since these conclusions have been drawn from mice generated to conditionally downregulate Brca1 expression in mammary epithelial cells, the issue whether modulated Brca1 expression would have consequences in other cell types remained unresolved.
Although the effects of modulated Brca1 expression were specific for mammary epithelial cells, we found Brca1 protein expression also to be upregulated during muscle and neuronal differentiation. The detection of high Brca1 expression does not allow conclusions about the functional role of this tumor suppressor for the differentiation of the according cell type or tissue. In addition, these findings fit to the observation that Brca1 is widely expressed in different tissues but mutations in this gene specifically cause breast and ovarian cancer (Zheng et al., 2000; Wang et al., 2000; Welcsh et al., 2001; Kerr and Ashworth, 2001 ). Brca1 mRNA expression is also upregulated during mammary epithelial cell differentiation of HC11 cells (Rajan et al., 1996) . This suggests that transcriptional control provides a major contribution to the here observed upregulation of Brca1 protein expression. However, comparison of the kinetics of mRNA and protein expression makes clear that post-transcriptional mechanisms are additionally involved in the regulation of Brca1 protein expression during HC11 differentiation (Rajan et al., 1996 and our study). Posttranscriptional regulation during differentiation is a well known phenomenon. For example, we have demonstrated earlier that expression of tuberin, the gene product of the tuberous sclerosis complex gene 2, is post-transcriptionally upregulated during neuronal differentiation in vitro, but is not regulated during differentiation of C2C12 myoblasts into myotubes and of F9 embryonal carcinoma cells into cells resembling parietal endoderm (Soucek et al., 1998) .
Brca1 expression is low in arrested and in G1 cells and is upregulated in proliferating cells via induction at the G1/S boundary (Gudas et al., 1996; Vaughn et al., 1996; Rajan et al., 1996) . We found that upon differentiation of mammary epithelial, muscle and neuronal cells Brca1 protein expression increases concomitant with downregulation of proliferation represented by a drop in the amount of S phase cells. Accordingly, Brca1 protein expression during differentiation is decoupled from its normal cell cycle dependent regulation. Furthermore, we know that downregulation of proliferation during differentiation is no prerequisite for upregulation of Brca1 protein expression. During differentiation of C2C12 myoblasts into myotubes steady state levels of Brca1 protein increase before cells are entirely arrested (Figure 2 ). In addition, during neuronal differentiation of N1E-115 cells Brca1 protein expression still increases at a state at which proliferation rates do not change anymore (Figure 3 and data not shown). These observations demonstrate that Brca1 protein expression in differentiating cells is regulated by proliferation-independent mechanisms. Overexpression of BRCA1 is known to negatively influence cellular proliferation (Holt et al., 1996; Aprelikova et al., 1999) . Since downregulation of proliferation is one hallmark of differentiation of HC11 cells, one could assume that BRCA1's capacities to affect proliferation and differentiation are coupled. BRCA1 could arrest proliferation of HC11 cells making them more susceptible to the differentiation process. Proliferation assays revealed that HC11 cells are not arrested by ectopic BRCA1 demonstrating that these two functions are independent. Interestingly, we found that HeLa cells, but neither HC11 nor C2C12 cells, are arrested upon high levels of BRCA1. Recently, it was shown that the ability of BRCA1 to suppress proliferation depend on the presence of pRb (Aprelikova et al., 1999) . Our finding that all three analysed cell lines express pRb protein could suggest that additional mechanisms/pathways are involved in BRCA1's cell type specific proliferation control. Here it is important to note that the here performed Western blot analysis only tells that pRb is expressed and phosphorylated and does not allow the conclusion that pRb is functional concerning all aspects of its function. Aspects such as putative inactivating mutations in pRb Figure 7 Specific effects of BRCA1 overexpression on mammary epithelial cells are not due to specific cell cycle arrest. (a) G418-selectable mammalian expression vectors, empty as negative control or harboring full-length human BRCA1 cDNA, were transfected into HeLa cells, HC11 cells and C2C12 cells. Starting with equal cell numbers (harvesting and reseeding) the cell pools were kept under selection and cell numbers were determined at day 5 (HeLa), at day 12 (HC11) and at day 12 (C2C12) by cell counting with a Casy Cell Counter and Analyser. Cell numbers are given as a percentage relative to the control experiments, set as 100%. Data of 2 -3 independent experiments are presented+standard deviations. (b) Hela cells, HC11 cells and C2C12 cells, logarithmically growing and grown to confluency, were analysed for pRb protein expression by Western blot analysis. Slower migrating hyperphosphorylated forms are labeled with 1 and faster migrating hypophosphorylated forms are labeled with 2. Amounts of loaded protein were investigated by reprobing with anti-a-tubulin antibody Figure 8 Overexpression of the BRCA1-D11 variant does not promote differentiation of mammary epithelial cells. (a) G418-selectable mammalian expression vectors, empty as negative control or harboring the human BRCA1-D11 cDNA, were transfected into HC11 cells. Transfected cells, kept under selection, were differentiated by adding differentiation medium 3 days after reaching confluency. Expression of ectopic BRCA1-D11 mRNA was proven by RT -PCR at day 7 of differentiation with set 1 of specific oligonucleotides (lanes 1 -3) and set 2 of specific oligonucleotides (lanes 4 -6). Lanes 1, 4=cells transfected with the empty vector control; lanes 2, 5=cells transfected with the BRCA1-D11 plasmid; lanes 3, 6=water control. (b) Transfected cells, kept under selection, were differentiated. Domes, specifically formed during differentiation of HC11 cells, were counted at day 7 and at day 9 of treatment with differentiation medium. The control experiments have been set as 100%. Data of nine independent experiments are presented+standard deviations Brca1 in mammary epithelial cell differentiation M Kubista et al or e.g. the known inactivation of pRb due to viral proteins (e.g. HeLa cells express HPV 18 E7 protein) cannot be investigated by this approach. On the other hand it is also not fully elucidated which pRbinactivating effect would interfere with the cooperation of BRCA1 and pRb in proliferation control (Aprelikova et al., 1999) . Interestingly, we found HeLa cells to be arrested upon ectopic BRCA1 although pRb is known to be functionally affected by HPV 18 E7 protein in these cells. Further investigations are indicated to clarify a putative role of pRb in BRCA1's effects on cell differentiation.
BRCA1 is phosphorylated in response to induction of cell cycle progression and DNA damage. In immunoblot analyses the slower migrating hyperphosphorylated form and the faster migrating hypophosphorylated form of BRCA1 can be separated (Chen et al., 1996; Ruffner and Verma, 1997; Thomas et al., 1997; Scully et al., 1997) . During differentiation of HC11 and N1E-115 cells we did not observe any changes in the relation of the two bands suggesting that phosphorylation of Brca1 is not regulated and is decoupled from its normal proliferation-dependend regulation. During differentiation of C2C12 cells we observed a shift from hypo-to hyperphosphorylated (or even super-hyperphosphorylated) forms of Brca1 (Figure 2 ). An additional slower migrating band reproducibly occured during C2C12 differentiation, but never occured during differentiation of HC11 or N1E-115 cells. This band appeared (day 3) after differentiation of C2C12 cells already started (detectable via myogenin expression, cell cycle arrest and cell morphology change). This C2C12-specific band is an additional slower migrating form which appears parallel to the disappearance of the fastest form (compare Figure 2) suggesting that it represents hyperphosphorylation. It occurs in C2C12 cells, in which modification of Brca1 expression does not affect the differentiation process. It could neither be detected in HC11 cells, in which modification of Brca1 expression affects differentiation, nor in N1E-115 cells, which remain unaffected by modified Brca1 expression. Accordingly, there is no correlation between the appearance of this additional band and the here described cell type specific effects of Brca1 on differentiation.
Our report raises the interesting aspect of differences between BRCA1's role/regulation during proliferation control and BRCA1's role/regulation during differentiation. The study of L Chodosh published the first description of this phenomenon (Rajan et al., 1996) . Using the same HC11 cells, which we also used in our study, they found that Brca1 mRNA expression is downregulated in serum arrested cells. In light of this observation, these findings predicted that Brca1 mRNA expression levels would remain low in differentating HC11 cells since they found proliferation to remain low. In contrast to this expectation, Brca1 mRNA expression was upregulated after induction of differentiation. These observations strongly suggested that upregulation of Brca1 expression observed in differentiating HC11 cells occurs by a proliferationindependent pathway. This was the first description that the regulation/role of Brca1 is different in cell cycle control and during differentiation in the same cell. We found such an independency also for Brca1 protein expression (known to be upregulated upon induction of proliferation, but we found it to be upregulated in non-cycling/differentiating cells) and for Brca1 protein phosphorylation (known to be downregulated upon cell cycle arrest, but we found it to remain unchanged in non-cycling/differentiating HC11 cells). Although all these data suggest it, an experimental proof that BRCA1 can trigger different effects depending on whether it acts during differentiation in specific medium (hormones...) or not was missing until we show here that ectopic BRCA1 can promote differentiation of HC11 cells although it does not cause proliferation arrest under logarithmic growth condition.
BRCA1 interacts with p53 and several experiments demonstrated a role for p53 in BRCA1-mediated control of tumorigenesis, cell cycle and apoptosis (Deng and Scott, 2000; Xu et al., 2001) . The fact that the here used HC11 cell line does not express functional p53 (Merlo et al., 1994) proves that p53 does not play a role for BRCA1´s effects on mammary epithelial cell differentiation of HC11 cells.
BRCA1 has been implicated in the regulation of apoptosis (Zheng et al., 2000; Wang et al., 2000; Welcsh et al., 2001; Kerr and Ashworth, 2001 ). In line with that, conditional downregulation of Brca1 expression has been shown to upregulate apoptosis in mammary epithelial cells (Xu et al., 1999a) . Apoptotic cells can be identified (among other approaches) microscopically by typical morphological features, such as cellular condensation (cell shrinkage) and formation of membrane bound vesicles (apoptotic bodies), or by detection of subdiploid cells on the flow cytometer after DNA staining. In the course of the here presented study microscopical investigation and flowcytometric analysis did not reveal signs of elevated apoptosis, neither upon BRCA1 overexpression nor as a consequence of antisense treatment (data not shown).
In conclusion the here presented data implicate Brca1 to be an essential and specific component of the regulation of mammary epithelial cell differentiation.
Materials and methods
Cells and tissue culture
HC11 cells are an immortalized line of normal murine mammary epithelial cells derived from the COMMA-1 D cell population, which differentiate in the presence of lactogenic hormones and produce b-casein. HC11 cells were grown in RPMI 1640 medium containing 10% calf serum, 5 mg/ml insulin and 10 ng/ml epidermal growth factor. Differentiation was induced 3 days after reaching confluency in medium containing 5 mg/ml insulin, 1 mg/ml hydrocortisone and 5 mg/ ml prolactin. Differentiation was monitored by detection of b-casein expression and of the formation of blister-like Brca1 in mammary epithelial cell differentiation M Kubista et al structures, called domes, which are believed to result from fluid secretion by mammary epithelial cells cultured on a plastic substrate (Danielson et al., 1984; Ball et al., 1988; Rajan et al., 1996) . C2C12 mouse myoblasts (American Type Culture Collection CRL 1772) were grown in DMEM medium containing 10% fetal calf serum. Differentiation into myotubes via cell fusion was induced by changing growth medium to DMEM with 2% horse serum. Differentiation was monitored by detection of myogenin expression. In addition, for quantification of morphological differentiation cell cultures were fixed with Bouin's solution and stained with hematoxylin solution. The percentage of nuclei in myotubes was determined by counting at least 300 nuclei in at least four different fields chosen random per experiment. Only myotubes with at least three nuclei were scored as fused (O'Neill and Stockdale, 1972; Nadal-Ginard, 1978; Soucek et al., 1998) .
N1E-115 mouse neuroblastoma cells (ATCC CRL 2263) were cultured in DMEM. Neuronal differentiation was induced by changing to DMEM containing 2% fetal calf serum and 1.25% DMSO. Differentiation could be monitored by upregulation of neurofilament protein expression. Quantification of morphological differentiation can be performed by counting neurons with long neurites (Kranenburg et al., 1995; Soucek et al., 1998) .
HeLa cells (human cervical carcinoma cells; ATCC CCL 2) were grown in DMEM supplemented with 10% calf serum and antibiotics (30 mg/l penicillin, 50 mg/l streptomycin sulphate).
Flow cytometry
For cytofluorometric analyses of DNA distributions, cells were harvested by trypsinization and fixed by rapid submersion in ice-cold 85% ethanol. After 1 h fixation at 7208C, cells were pelleted and DNA was stained in 1 ml of staining solution (0.25 mg/ml propidium iodide, 0.05 mg/ml RNase, 0.1% Triton X-100 in citrate buffer, pH 7.8).
Western blot analyses
Protein extracts were prepared in buffer containing 20 mM HEPES, pH 7.9, 0.4 M NaCl, 2.5% glycerol, 1 mM EDTA, 1 mM phenylmethylsulfonylfluoride, 0.5 mM NaF, 0.5 mM Na 3 VO 4 , 0.02 mg/ml leupeptin, 0.02 mg/ml aprotinin, 0.003 mg/ml benzamidinchloride, 0.1 mg/ml trypsin inhibitor and 0.5 mM DTT. Cells were lysed by freezing and thawing, the extracts were centrifuged and the supernatants were stored at 7708C. Protein concentrations were determined using the Bio-Rad protein assay reagent with bovine serum albumin as the standard. Proteins were run on an SDSpolyacrylamide gel and transferred to nitrocellulose. Blots were stained with Ponceau-S to visualize loaded protein.
Immunodetection was performed using anti-BRCA1-antibody (C-20, Santa Cruz), anti-BRCA1-antibody (H-100, Santa Cruz), anti-myogenin-antibody (M-225, Santa Cruz), anti-a-tubulin-antibody (Ab-1, Calbiochem), anti-neurofilament-antibody (Ab-2, NeoMarkers), anti-pRb-antibody (G3-245, Pharmingen). Signals were detected using the enhanced chemiluminescence method (Amersham).
Northern blot analyses
RNA, prepared using TriReagent (Molecular Research Center, Inc.), was denatured in 1 M deionized glyoxal, 4.8% DMSO and 10 mM sodium phosphate (pH 6.8) for 1 h at 508C. RNA was resolved on a 1.2% agarose gel in 10 mM sodium phosphate (pH 6.8), transferred to nylon in 20 6 SSC and immobilized by UV fixation. Filters were hybridized in 1% BSA, 7% SDS, 0.5 M sodium phosphate buffer (pH 6.8) and 1 mM EDTA for at least 10 h at 658C. After successive washing in 0.5% BSA, 5% SDS, 40 mM sodium phosphate (pH 6.8), 1 mM EDTA, and in 1% SDS, 40 mM sodium phosphate (pH 6.8), 1 mM EDTA at 658C filters were exposed. The hybridization cDNA probe was specific for bcasein.
Transfections
For transfections the following plasmids were used: the empty CMV-expression vector pcDNA3; pcDNA3 harboring full-length wild-type human BRCA1 cDNA (Aprelikova et al., 1999) ; pcDNA3 harboring the human variant BRCA1-D11 lacking the large central exon 11 (Bochar et al., 2000) . Cell transfections were performed using the LipofectAMINE reagent obtained from Life Technologies (Gibco BRL) following the transfection protocol provided by the manufacturer. Selection for transfected cells was started 24 h after transfection. The G418 concentration was optimized for every different cell line and the obtained transfected cell pools were kept under selection.
RT -PCR
For the detection of mRNA expression of the transfected BRCA1 cDNAs (full-length and the D11-variant) RNA was prepared as described above. Two different sets of primers were designed for the specific detection of the ectopic constructs and purchased from MWG-Biotech GmbH (Germany). First-strand cDNA synthesis and PCR was performed using the RT-Mix from ViennaLab (Vienna, Austria) following the protocol provided by the manufacturer. b-casein mRNA expression was determined by semiquantitative RT -PCR with primers and reagents obtained as described above. As internal standards the expression of b-actin and of 18S-rRNA was analysed.
Proliferation assays
Proliferation assays were performed as described earlier (Miloloza et al., 2000) . Selection for transfected cells was started 24 h after transfection. Starting with equal cell numbers (harvesting and reseeding) the cell pools were kept under selection and cell numbers were determined at the indicated time points by cell counting on a Casy Cell Counter and Analyser. For cell counting cells growing in petri dishes were washed with buffer and harvested by trypsinization. Cell numbers are given as a percentage relative to the control experiments, set as 100%.
Antisense treatment
The used antisense oligonucleotide GACGGCAGATAAATC-CAT is specific for the start region of murine Brca1. The antisense oligonucleotide specific for the corresponding region in human BRCA1 has been shown to significantly downregulate BRCA1 expression (Thompson et al., 1995) . The control oligonucleotide was of the same length with the same proportion of the four basepairs, but randomly organized. The oligonucleotides were purchased from Biognostik GmbH (Go¨ttingen, Germany). Phosphorothioate oligomers were used to ensure sufficient stability against intracellular DNAses. We routinely used 2 mM oligonucleotides, which induced significant downregulation of Brca1 expression.
